Gilead Sciences’ cell-therapy subsidiary Kite Pharma has agreed to buy privately held Interius BioTherapeutics for $350 million in cash, gaining a platform that engineers CAR T cells directly inside patients’ bodies. Interius’ technology, already being tested in a Phase 1 study of blood cancers, uses engineered viruses to deliver genetic instructions that transform immune cells in vivo. Its lead program, INT2104, has dosed patients with B-cell malignancies in Australia. Kite said the deal will trim Gilead’s 2025 earnings per share by roughly 23 to 25 cents. Closing is subject to antitrust clearance, after which Interius’ staff and facilities will form a Philadelphia-based center of excellence within Kite. The purchase is the latest sign of large-pharma interest in in-vivo cell therapy, following AstraZeneca’s $425 million acquisition of EsoBiotec in March and AbbVie’s $2.1 billion buyout of Capstan Therapeutics in June.